Uniqure NV

NASDAQ QURE

Data sourced from

and

Download Data

Uniqure NV Cash to Debt Ratio 5 year CAGR for the quarter ending March 31, 2024: -16.05%

Uniqure NV Cash to Debt Ratio 5 year CAGR is -16.05% for the quarter ending March 31, 2024, a 40.91% change year over year. The cash to debt ratio assesses a company's ability to cover its total debt obligations with its available cash. It is calculated by dividing cash by total debt. This ratio indicates the company's liquidity and its capacity to meet its debt obligations using its cash reserves. A higher cash to debt ratio suggests a stronger ability to cover debts with cash resources. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.

Uniqure NV Cash to Debt Ratio for the quarter ending March 31, 2023 was 1.39, a -71.68% change year over year.
Uniqure NV Cash to Debt Ratio for the quarter ending March 31, 2022 was 4.90, a 42.57% change year over year.
Uniqure NV Cash to Debt Ratio for the quarter ending March 31, 2021 was 3.44, a -57.71% change year over year.
Uniqure NV Cash to Debt Ratio for the quarter ending March 31, 2020 was 8.12, a 53.43% change year over year.

NASDAQ: QURE

Uniqure NV

CEO	Mr. Matthew Craig Kapusta
IPO Date	June 20, 2007
Location	Netherlands
Headquarters	Paasheuvelweg 25a, Amsterdam, Netherlands, 1105 BP
Employees	480
Sector	Healthcare
Industry	Biotechnology

Description

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Key trends